Rein therapeutics reports fourth quarter and full year 2024 financial results and provides business update

Rein advanced the clinical development of its lead asset, lti-03, and aims to initiate a phase 2 trial for the treatment of idiopathic pulmonary fibrosis (ipf) in the first half of 2025 positive topline results from cohort 2 (5 mg bid) of the phase 1b clinical trial of lti-03 in ipf patients demonstrated dose dependent effects in five biomarkers evaluated, with four biomarkers achieving statistical significance in the combined cohort 1 and cohort 2 data set austin, texas , april 7, 2025 /prnewswire/ -- rein therapeutics, inc. (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended december 31, 2024 and provided a business update. "we've made significant clinical progress during 2024, culminating in promising safety and positive topline data from our phase 1b trial of lti-03 in ipf patients, which demonstrated early signs of therapeutic effect.
RNTX Ratings Summary
RNTX Quant Ranking